Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

ments, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial for patients with recurrent or metastatic NSCLC with K-RAS or EGFR-activated tumours, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... researchers have observed the fractional quantum Hall effect in ... matter can be tuned by an electric field. ... when electrons confined to thin sheets are exposed to ... behavior where thousands of individual electrons behave as a ... effect is well established, many details of this collective ...
(Date:7/10/2014)... two universities and NPL collaborate to bring together their ... their complementary academic strengths., Working with BIS and NPL ... priorities of the UK. The establishment of a Graduate ... students, will provide a pipeline of skilled researchers. Working ... Laboratory will be grown through the creation of a ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... Oct. 19 Reportlinker.com announces that ... available in its catalogue: ... Increased Demand for Biologics Drives Improvement ... http://www.reportlinker.com/p0316266/Downstream-Processing-in-Biopharmaceuticals---Increased-Demand-for-Biologics-Drives-Improvement-in-Cost--effective-Purification-Technologies.html ...
... In an astounding case of callous disregard for U.S. ... denied registration of the trademark "China-Free"* submitted by the ... customers with an informed choice for obtaining vitamins containing ... was refused because it was deemed to be "disparaging" ...
... its breakthrough placenta stem cell preservation process, the first of its ... cord blood stem cell banking. The new process, called Cord ... the placenta than is found on average in a unit of ... patient weighing less than 65 pounds. As a result of this ...
Cached Biology Technology:Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 2Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 3Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 4Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 5Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 6Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 7Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies 8According to Opurity, Feds Put U.S. Consumers at Risk: PTO Bureaucrats Refuse to Approve Vitamin Company's 'China-Free' Trademark 2Americord Registry Becomes First Cord Blood Bank to Offer Placenta Preservation, Advancing Cord Blood Stem Cell Therapy Options 2
(Date:7/11/2014)... SEATTLE, WASH. July 11, 2014 Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
(Date:7/11/2014)... the marginal division of the striatum is also ... impact degree of substance P in the striatal ... Yu and his team, College of Biophotonics, South ... that substance P receptor, neurokinin 1 was highly ... of normal rats. Unilateral or bilateral injection of ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... of life in extreme environments, scientists have discovered abundant and ... lake sealed under more than 65 feet of ice. ... Proceedings of the National Academy of Sciences , is surprising ... from the surface environment -- and external sources of energy ...
... juicier, sweeter, more disease-resistant watermelons on the way? An ... United States, China, and Europe has published the genome ... that could dramatically accelerate watermelon breeding toward production of ... watermelon genome sequence was published in the Nov. 25 ...
... SAN DIEGO, Calif. (November 26, 2012) The Algae Biomass Organization, ... the findings of a University of California at San Diego ... algae can be just as capable as freshwater algae in ... published online in the current issue of the scientific journal ...
Cached Biology News:UIC scientists find ancient microbes in salty, ice-sealed Antarctic lake 2Genome decoded: Scientists find clues to more disease-resistant watermelons 2Algae Biomass Organization hails new UCSD study showing saltwater algae viable for biofuels 2
... acetylcholinesterase (AChE) activity. This is a highly ... non-radioactive and easy to use assay for ... acetylcholine. A series of coupled enzyme reactions ... a change in luminescence. Inhibitors of AChE ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
Biology Products: